50. Dermatomyositis Clinical trials / Disease details

Clinical trials : 194 / Drugs : 244 - (DrugBank : 89) / Drug target genes : 50 - Drug target pathways : 151

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-000391-15-IT (EUCTR)	05/06/2018	27/02/2018	Multicentric, prospective open-label study to assess the efficacy and safety of Tocilizumab in subjects with refractory myositis	Multicentric, open-label, prospective study of subcutaneous tocilizumab in adult patients with refractory myositis - ToReMy	Myositis (dermatomyositis [DM] or polymyositis [PM]) MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 20.0;Classification code 10028653;Term: Myositis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0;Classification code 10036102;Term: Polymyositis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: RoActemra 162 mg soluzione iniettabile in siringa preriempita Product Name: RoActemra 162 mg soluzione iniettabile in siringa preriempita Product Code: NA INN or Proposed INN: Tocilizumab Other descriptive name: TOCILIZUMAB	Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia	NULL	Not Recruiting			Female: yes Male: yes	16	Phase 2	Italy
2	NCT02043548 (ClinicalTrials.gov)	October 1, 2014	17/1/2014	Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis	Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis	Dermatomyositis;Polymyositis	Drug: tocilizumab;Drug: placebo	Chester Oddis	Genentech, Inc.	Completed	18 Years	N/A	All	36	Phase 2	United States